Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD

被引：0
作者：
Dave Singh
Gabriele Nicolini
Eddi Bindi
Massimo Corradi
Daniele Guastalla
Jorg Kampschulte
Władysław Pierzchała
Abdullah Sayiner
Mária Szilasi
Claudio Terzano
Jørgen Vestbo
机构：
[1] University Hospital of South Manchester Foundation Trust,University of Manchester, Medicines Evaluation Unit
[2] Chiesi Farmaceutici S.p.A,Corporate Clinical Development
[3] University of Parma,Department of Clinical and Experimental Medicine
[4] Chiesi Farmaceutici S.p.A,Corporate Marketing
[5] Praxis Dr,Department of Chest Diseases
[6] Niepubliczny Zakład Opieki Zdrowotnej “PROFILAKTYKA”,Department of Respiratory Medicine
[7] Ege University Faculty of Medicine,undefined
[8] Debreceni Egyetem Orvos és Egészségtudományi,undefined
[9] U.O.C. Malattie Respiratorie Policlinico Umberto I- Università degli Studi di Roma “La Sapienza”,undefined
[10] Odense University Hospital / University of Southern Denmark,undefined
[11] the FUTURE (Foster Upgrades TherapeUtic care in REspiratory disease) study group,undefined
来源：
BMC Pulmonary Medicine | / 14卷
关键词：
Chronic Obstructive Pulmonary Disease; Chronic Obstructive Pulmonary Disease Patient; Salmeterol; Formoterol; Chronic Obstructive Pulmonary Disease Exacerbation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 236 条
  • [1] Vestbo J(2013)Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary Am J Respir Crit Care Med 187 347-365
  • [2] Hurd SS(2011)Symptom variability in patients with severe COPD: a pan-European cross-sectional study Eur Respir J 37 264-272
  • [3] Agusti AG(2013)Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials Thorax 68 48-56
  • [4] Jones PW(2002)Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids Eur Respir J 19 182-191
  • [5] Vogelmeier C(2006)Interactions between long-acting β2 agonists and glucocorticoids Drug Discov Today Ther Strateg 3 261-268
  • [6] Anzueto A(2008)Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis JAMA 300 2407-2416
  • [7] Barnes PJ(2009)Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis Arch Intern Med 169 219-229
  • [8] Fabbri LM(2010)Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update Curr Opin Pulm Med 16 118-122
  • [9] Martinez FJ(2012)Combined corticosteroid and long-acting beta(2) agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease Cochrane Database Syst Rev 12 CD006829-17
  • [10] Nishimura M(2013)A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations Eur Respir J 41 12-1868
12345678910